| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;95:265-272.)
© 1997 American Heart Association, Inc.
Articles |
Survivors of Out-of-Hospital Cardiac Arrest With Apparently Normal Heart
Need for Definition and Standardized Clinical Evaluation
Correspondence to Silvia G. Priori, MD, PhD, FESC, Molecular Cardiology Unit, Cardiovascular Laboratories, Fondazione S. Maugeri, IRCCS, and Department of Cardiology, Policlinico S. Matteo, IRCCS, Piazzale Golgi 2, 27100 Pavia, Italy.
 |
Abstract |
|---|
Top
Abstract
IntroductionBackground A wide variety of structural abnormalities are associated with the vast majority of cardiac arrests. However, there is no evidence of structural heart disease in
5% of victims of sudden death, indicating that cardiac arrest in the absence of organic heart disease is more common than previously recognized. The risk of recurrence and the acute and long-term response to therapy are important but unanswered questions. Data from the small series reported so far are of limited value because of the lack of uniform criteria to define and diagnose idiopathic ventricular fibrillation (IVF). Methods and Results This report originates from a Consensus Conference convened by the Steering Committees of the European (UCARE) and North American (IVF-US) Registries on IVF under the auspices of the Working Group on Arrhythmias of the European Society of Cardiology. Its objective is to provide a unified definition of IVF and to outline the investigations necessary to make this diagnosis. Minimal diagnostic tests for the exclusion of an underlying structural heart disease include noninvasive (blood biochemistry, physical examination and clinical history, ECG, exercise stress test, 24-hour Holter recording, and echocardiogram) and invasive (coronary angiography, right and left ventricular cineangiography, and electrophysiological study) examinations. Programmed electrical stimulation, ventricular biopsy, and ergonovine test during coronary angiography are recommended but not mandatory.
Conclusions It is recognized that despite careful evaluation, conditions such as focal cardiomyopathy, myocarditis, or fibrosis and transient electrolyte abnormalities may remain silent. Therefore, patients should undergo careful follow-up, with noninvasive tests repeated every year. The existence of a unified terminology will allow meaningful comparison of data collected by different investigators and will thus contribute to a better understanding of IVF.
Key Words: fibrillation • death, sudden • arrhythmia • diagnosis
|
Introduction |
|---|
More than 90% of sudden cardiac deaths occur in patients with known or previously unrecognized preexisting coronary heart disease or cardiomyopathies. Among the remainder, it has become evident that sudden arrhythmic death occurs with sufficient frequency in patients with an apparently normal heart to warrant the attention of the cardiological community. This is further supported by the tendency for such fatal events to occur in special groups, such as young, active, and otherwise healthy individuals.
The most pressing questions about this entity concern the risk of recurrence, the acute and long-term responses to the various therapies currently used, and the intriguing possibility that in some patients VF may represent the first clinical sign of structural disease that becomes manifest only several years later among survivors.
The Working Group on Arrhythmias of the European Society of Cardiology recognized the clinical relevance of these questions and in 1992 formally established a prospective long-term registry of this clinical entity with the goal of addressing this problem.1 This project is named UCARE and has already enrolled more than 160 patients who survived an episode of IVF. Preliminary data2 3 suggest that IVF is associated with a high (25% to 30%) risk of recurrence of cardiac arrest. In 1994, a group of investigators in the United States decided to initiate a similar registry (IVF-US).
A clear and unified definition of "an apparently normal heart" is essential to avoid the misdiagnosis of IVF in a survivor of a cardiac arrest due to a specific clinical entity for which an appropriate treatment may have already been established. Accordingly, the Steering Committees of the European and the American registries formed a panel to establish the criteria necessary for the diagnosis of "cardiac arrest with an apparently normal heart." The meeting stimulated the creation of the present document, whose main objective is to propose a set of standardized diagnostic criteria.
|
Background |
|---|
A wide variety of structural abnormalities are associated with the vast majority of cardiac arrests.4 However, it is necessary to deal with the fact that there are also functional causes not associated with pathological anatomic changes.
Sudden arrhythmic death in the absence of structural heart disease is an uncommon event. However, data from large series of patients resuscitated from cardiac arrest and necropsy data from victims of sudden death indicate that there is no evidence of structural heart disease in 5% of victims of sudden death.5 6 7 8 9 10 11 12 Thus, cardiac arrest in the absence of structural heart disease may be more common than previously recognized. This subgroup of survivors of out-of-hospital cardiac arrest deserves to be carefully evaluated to define their optimal long-term management and outcome,13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 because their survival is largely related to potentially controllable electrophysiological disturbances, rather than limited by the competing risk of advanced myocardial disease.30
The data already available in UCARE, based on >160 patients, represent the largest collective experience on IVF. According to the UCARE investigators, after 3 years from cardiac arrest, IVF patients have 30% recurrence of VF, syncope, and cardiac arrest, and prevention of recurrence is inadequate with the use of antiarrhythmic agents, including ß-blockers.2 These data are at variance with the experience of Belhassen and Viskin,31 who reported favorable effects of sodium channel blockers, but they are in agreement with previous observations28 29 suggesting a high recurrence rate of malignant tachyarrhythmias in IVF survivors and raising the possibility that IVF patients should be considered candidates for an implantable defibrillator.2 It is therefore important to produce guidelines to define the criteria to separate IVF from other conditions in which VF may be the first manifestation of the disease.
|
Definitions |
|---|
Several terms have been proposed to describe those patients who survive an episode of ECG-documented VF with an apparently normal heart. The language used to define such patients is not merely semantic; it has operational connotations for both clinical and research purposes.
Primary electrical disease implies that there is no recognizable structural heart disease to account for the arrhythmic event and that an electrophysiological mechanism is solely responsible for the arrhythmic episode. The limitation of this definition is that it is impossible to exclude causes such as transient autonomic abnormalities as the initiating mechanism for the arrhythmia. Moreover, this definition could be extended to atrial arrhythmias such as lone atrial fibrillation and to benign idiopathic arrhythmias such as isolated premature ventricular complexes and idiopathic nonsustained VT.
Arrhythmic death without identifiable heart disease is another term that reflects the lack of identification of a cardiac disease. It has the advantage of considering that a minimal structural abnormality can be responsible for the development of the arrhythmia; however, "arrhythmic death" may also include arrhythmias other than VF, such as sinus arrest or complete AV block.
IVF is the terminology that best acknowledges our current inability to identify a causal relationship between the clinical circumstance and the arrhythmia. The advantage of this definition is that the term IVF does not imply that the heart of the patient is completely free of structural or definable functional abnormalities but simply that, if an abnormal finding (such as first-degree AV block or paroxysmal atrial fibrillation) is present, it is not considered responsible for the VF.
Thus, in the absence of clinical or laboratory findings that could account for the occurrence of major arrhythmic events, the diagnosis of IVF can be made once a survivor of cardiac arrest has been extensively studied.
These considerations emphasize the concept that there may be no distinct and fixed border between normal and frankly abnormal. Moreover, the border may change over time, and new data emerging on membrane-based functional32 33 or structural abnormalities34 35 may ultimately provide more specifically defined explanations.
A disease is "idiopathic" because present knowledge has not yet allowed identification of the underlying cause. Eventually, the cause of most idiopathic disorders will be known. For example, the LQTS, which was considered idiopathic until the three genes responsible for most cases were identified,36 37 38 39 is no longer so. Thus, IVF is an appropriate "initial" or "working" diagnosis that reflects our current inability to establish a link between clinical information obtained by detailed invasive or noninvasive examinations and a life-threatening arrhythmic event.
We include in the IVF group only individuals with a documented VF, even though it cannot be ruled out that the arrhythmic episode might have started as VT or even asystole. We believe that, despite being an arbitrary distinction, this criterion originates from the idea that it is the degeneration into VF that represents the common denominator for this group of patients.
|
Evaluation of the Arrhythmogenic Substrate in Survivors of Cardiac Arrest |
|---|
IVF is a diagnosis of exclusion. Therefore, it is of pivotal importance to define the conditions that have to be excluded as well as the most appropriate techniques for excluding them.
There is no need to exclude every cardiac abnormality but rather only those conditions known to be associated with sudden death.
|
Use and Abuse of Drugs |
|---|
Before any medical or invasive investigation is undertaken, it is critical to obtain a careful clinical history. Indeed, a link between the use of pharmacological substances and the development of VF may be suspected simply by questioning the patient with regard to exposure to substances or drugs in the days before the index event. Many drugs are known to favor development of torsade de pointes: among these are quinidine, phenothiazines, antibiotics like erythromycin and other macrolides,40 and antihistamines,41 either alone or in combination with antifungal drugs of the "conazole" type.42
The link between alcohol abuse and lethal ventricular tachyarrhythmias has been suggested but not conclusively demonstrated. A few studies43 44 45 reported that lethal ventricular arrhythmias may precede signs of alcoholic cardiomyopathy. It is important to obtain urine toxicology in patients suspected of drug abuse.
|
Ischemic Heart Disease |
|---|
Coronary angiography is necessary for establishing the presence or absence of coronary heart disease and to detect congenital coronary anomalies. Among patients with typical angina pectoris or with multiple risk factors for ischemic heart disease, the results of noninvasive tests help to quantify the probability of ischemic heart disease. However, in the heterogeneous population of patients with unexplained cardiac arrest whose demographic and clinical profiles are often quite different from those of patients at risk for ischemic heart disease, the pretest probability of coronary artery disease is undefined. Thus, according to Bayesian theory, results of noninvasive tests such as exercise stress test and myocardial scintigraphy with thallium may not be helpful in the diagnostic process.46 Therefore, it is recommended that coronary angiography be performed in all patients, of any age, with unexplained cardiac arrest to establish whether or not there is ischemic heart disease.
IVF will be excluded in the presence of (1) an unequivocal clinical history of ischemic heart disease, (2) definite evidence of acute myocardial ischemia or necrosis on the 12-lead ECG unless enzyme elevation is due to defibrillation shocks,47 and (3) anatomic alterations in the coronary arterial tree that are considered to be clinically important.
It is reasonable to define a narrowing of 
50% in at least one coronary artery as excluding the diagnosis of IVF.15 The significance of minor stenoses with narrowing in the range of 25% to 49% is difficult to assess, because they may be thrombogenic and/or favor coronary spasm. The definition of IVF in these cases must be left to the judgment of the responsible clinician. In this respect, testing for provocation of coronary artery spasm may be important to identify silent myocardial ischemia or atypical symptoms,48 and patients with a positive test should be excluded. Careful follow-up of patients suspected of ischemic heart disease may identify signs and symptoms of ischemia shortly after the index event.
It has been suggested that myocardial perfusion heterogeneity and impaired perfusion reserve may be present in IVF survivors49 ; however, no conclusive data have established a causal link between ventricular tachyarrhythmias and microvascular disease. At present, therefore, there is no indication for routine PET studies to exclude this condition.
Coronary arteries may be "bridged" by muscle bands.50 Although systolic narrowing of normal coronary arteries does not result in myocardial ischemia in most individuals, in the absence of chest pain it is unlikely that bridging is the cause of asymptomatic ischemia precipitating cardiac arrest. When this abnormality is diagnosed or suspected at angiography, however, it is mandatory to exclude by scintigraphy the presence of myocardial ischemia.
|
Dilated Cardiomyopathy |
|---|
The conventional diagnosis of myocardial disease depends on the demonstration of ventricular dilatation and reduced contractile function by ventriculography or two-dimensional echocardiography, in the absence of coronary artery disease. Assessment of ventricular function must be done
48 hours after the arrest, since prolonged (15 minutes) resuscitation in otherwise healthy subjects produces myocardial stunning that takes at least 48 hours to recover and is associated with transient systolic and diastolic dysfunction.51 In an early phase of the disease, there may be more subtle features, such as an ejection fraction <50% or mild cavity enlargement (increase of volumes <20%). |
Hypertrophic Cardiomyopathy |
|---|
Sudden cardiac death is a common initial presentation of hypertrophic cardiomyopathy, particularly in the young. The clinical diagnosis in survivors is based on history, physical examination, 12-lead ECG, and two-dimensional echocardiographic/Doppler evaluation.52 The majority of individuals who have suffered out-of-hospital VF from hypertrophic cardiomyopathy will fulfill conventional diagnostic criteria, eg, unexplained left ventricular hypertrophy. Occasionally, and particularly in those families with mutations in the cardiac troponin T gene, the echocardiographic features do not fulfill current diagnostic criteria.35 In such instances, suggestive features such as mild increase in left ventricular wall thickening, small left ventricular cavity dimensions, incomplete systolic anterior motion of the mitral valve, or diastolic abnormalities including atrial enlargement should lead to consideration of the diagnosis, with particular attention to family history, symptoms (endurance exercise tolerance), and minor ECG abnormalities (repolarization changes, intraventricular conduction defects, abnormal Q waves).
A range of mutations in four different contractile protein genes have been shown to cause disease. It is technically possible to screen the ß-myosin heavy chain, cardiac troponin T, cardiac 
-tropomyosin, and myosin-binding protein C genes for mutations. This, however, is still a research procedure and at present cannot be offered as a routine clinical service. The identification of the remaining genes and more cost-effective ways of screening for mutations should in the future lead to a DNA diagnostic that could be applied to survivors of out-of-hospital VF in whom there is diagnostic uncertainty.
|
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy |
|---|
The first clinical sign of ARVD, which is also called right ventricular cardiomyopathy, is often the occurrence of VT of right ventricular origin, frequently elicited by exercise; subtle abnormalities of the right ventricle may also be present, and cardiac arrest may be the presenting clinical manifestation.53 54 This diagnosis should always be sought among survivors of cardiac arrest.55
The histological demonstration of (fibro)-fatty replacement of right ventricular myocardium allows definite diagnosis of right ventricular dysplasia/cardiomyopathy. The disease can be overlooked unless the right ventricle is specifically assessed during imaging studies. An echocardiogram of the right ventricle may reveal hypokinetic areas or dilatation in the free wall of the right ventricle and in the infundibulum. A normal echocardiogram does not exclude the diagnosis of ARVD. Right ventricular cineangiography with 30° right anterior oblique and 60° left anterior oblique views provides the most appropriate way to identify motion abnormalities of the right ventricle. ECG abnormalities such as inverted T waves in V2 and V3 in patients >12 years old without RBBB and prolongation of the QRS (>110 ms) in V2 and V3 have been suggested as major criteria for the diagnosis of ARVD by the Task Force of the Working Group for Myocardial and Pericardial Diseases.53 In the less obvious forms of the disease, the diagnosis is based on the simultaneous presence of a constellation of abnormal findings that, by themselves, would be nondiagnostic. The role of MRI in the diagnosis of ARVD still needs to be defined56 57 ; therefore, this investigation cannot be considered necessary before this diagnosis has been excluded.
In 30% of cases the disease is familial, with an autosomal dominant inheritance; the genetic abnormality has been located in yet unknown genes on chromosome 1458 and chromosome 1.59
|
LQTS/Prolonged-QT Interval |
|---|
QT-interval prolongation, history of stress-induced syncope, and family history are the mainstays for the diagnosis of the Romano-Ward form of the congenital LQTS.60 In the presence of a markedly prolonged QT interval and of typical abnormalities of T-wave morphology, the diagnosis is rather straightforward. The problem remains the diagnosis of equivocal cases.
Careful evaluation of the 12-lead ECG is critical. QT and QTc duration and dispersion61 should be assessed. QTc values >440 ms for men and >460 ms for women are considered to be prolonged.62 The diagnosis of questionable LQTS cases is still problematic. Careful evaluation of repeated 12-lead ECGs of the patient and family members and repeated Holter monitoring remain of critical importance. In borderline cases, attention should be paid to identify abnormal T-wave morphologies, such as T-wave alternans63 and notches on the T wave,64 65 and sudden pauses during Holter monitoring60 that may contribute importantly to the diagnosis. An exercise stress test is also required because QT prolongation or T- or U-wave abnormalities may appear during exercise or at its cessation.
The recent identification of three of the genes responsible for LQTS cases36 37 38 39 opens the possibility for genetic diagnosis. However, molecular diagnosis is still largely a research tool.66
Several drugs, including noncardiovascular drugs, prolong the QT interval and cause cardiac arrest40 41 42 ; a complete list of current medications should always be obtained in patients with QT prolongation and cardiac arrest. In addition, electrolyte imbalance, such as hypokalemia or hypocalcemia, can also prolong repolarization. Accordingly, the presence of a prolonged QT interval should be considered a strong factor against the diagnosis of IVF.
|
Idiopathic Ventricular Tachycardia |
|---|
Several forms of VT are included in this group, such as verapamil-sensitive VT,67 fascicular tachycardia of RBBB configuration with left or right axis deviation,68 and right ventricular outflow tract tachycardia.69 Irrespective of their site of origin, all these tachycardias share a benign prognosis.70 In contrast, several types of polymorphic idiopathic VT have been described and are associated with a poor outcome.71 72 73 They can occur as sporadic or familial forms and are frequently precipitated by catecholamine release during physical or emotional stress, although this is not a consistent feature. The short-coupled variant of torsade de pointes73 shares several clinical and ECG characteristics with those described in idiopathic VF by Belhassen et al.74 On the other hand, the straightforward relationship between arrhythmia precipitation and stress, as well as the reproducible provocation of atrial and ventricular arrhythmias by exercise or isoproterenol infusion in children with the catecholaminergic polymorphic VT,71 merits a separate classification. Patients with catecholaminergic polymorphic VT have a favorable response to treatment with ß-blockers, whereas patients with idiopathic VF or short-coupled torsade de pointes do not.
|
Sudden Unexplained Nocturnal Death Syndrome |
|---|
Sudden unexplained nocturnal death syndrome is a sudden unexplained nocturnal death in young, apparently healthy males75 76 77 78 of Southeast Asian origin. These deaths are named lai-tai (sleep death) in Laos, pokkuri (sudden and unexpected death) in Japan, and bangungut (to rise and moan in sleep) in the Philippines. Death is unexpected, because the victims are in apparently good health. The immediate symptoms are onset of agonal respiration during sleep. Some victims are revived by vigorous cardiac massage and then reported a sensation of airway obstruction, chest pressure, and numb or weak limbs. The cause for sudden unexplained nocturnal death syndrome is still unknown; however, the peculiar geographic distribution of these patients and the type of symptoms, including night terrors, nightmares, and nocturnal vocalizations,77 78 suggest that this diagnosis should be kept separate from IVF.
|
Ventricular Preexcitation |
|---|
In patients with presumed IVF, the possibility of an accessory AV connection should include careful evaluation of the 12-lead surface ECG for the presence of a delta wave, and an electrophysiological study is suggested. The latter is important, considering that antegradely conducting accessory pathways, especially left-sided pathways, may not be apparent in a 12-lead ECG performed during sinus rhythm.79 An electrophysiological study is performed to identify an accessory AV connection and recognize risk factors for sudden death80 (short anterograde refractory period of the accessory pathway, ie, <250 ms; a preexcited RR interval of
250 ms during spontaneous or pacing-induced AF episodes; and fast AV reciprocating tachycardia associated with poor cardiac output). In nonconclusive cases, reassessment using isoproterenol infusion may be useful.81 Patients with supraventricular tachycardia but with a history of VF during exercise should be suspected of having supraventricular tachycardia degenerating into VF, because exercise enhances AV nodal conduction. |
Myocarditis |
|---|
The strongest evidence that subclinical myocarditis can be a cause of VF comes from an autopsy series82 on US army recruits in which 40% of those who died suddenly had histological evidence of myocarditis. However, in those subjects who were ostensibly normal before death, the status of ventricular function was unknown. Therefore, the question remains whether myocarditis can lead to VF when all other clinical parameters are normal.
The gold standard for the diagnosis of myocarditis remains myocardial biopsy (immunochemical stains are essential), which is highly specific.83 84 However, because of the patchy involvement of the myocardium, biopsies have a low sensitivity, and therefore a negative biopsy cannot be considered a definitive criterion for excluding myocarditis.85 86 87 In several cases, the origin of the arrhythmias defined during the electrophysiological study is not concordant with the site of histological abnormality; thus, it may be difficult to establish a causal relationship between bioptic findings and arrhythmias.
In the future, polymerase chain reaction gene amplification may allow identification of the viral genome from biopsy samples88 and may help in interpreting borderline findings.
|
Infiltrative Diseases |
|---|
Infiltrative diseases are generally detectable when major changes of the myocardial structure have occurred. In patients with sarcoidosis, a stepwise imaging investigation89 could be performed to exclude cardiac involvement. Myocardial biopsy should also be considered for the diagnosis of sarcoidosis, even in the absence of pulmonary evidence of the disease or a negative response to a skin test.
|
Minimal Diagnostic Requirements For the Diagnosis of IVF |
|---|
On the basis of the criteria outlined above, a panel of tests should be performed in patients with unexplained cardiac arrest to exclude clinical conditions associated with sudden cardiac death.
Although noninvasive tests might establish a diagnosis and avoid the need for invasive tests, the majority of patients without an obvious cause of cardiac arrest will undergo invasive testing (Table 1
).
|
|
Recognition and Interpretation of Minimal Cardiac Abnormalities |
|---|
One of the major steps in defining VF as "idiopathic" should be to clarify possible causal relationships that are currently unrecognized or controversial. In addition to nonspecific bioptic findings, the significance of minor hemodynamic abnormalities, such as borderline right and left ventricular indexes and subtle wall motion abnormalities, is unclear in survivors of IVF. Furthermore, the prevalence of subtle abnormalities in comparable individuals without life-threatening arrhythmias is not known.
An example of a minor abnormality frequently encountered in normal individuals that may pose the question of a causal relationship with cardiac arrest is mitral valve prolapse. A causal relationship between mitral valve prolapse and sudden death has not been established unless the prolapse is associated with valve redundancy, thickening, and regurgitation; QT prolongation; or ST-T wave changes.90 91 92 93 94 95 General agreement exists that paroxysmal and chronic atrial fibrillations have no specific relation to sudden death in the absence of the Wolff-Parkinson-White syndrome or hyperthyroidism or in subjects <70 years old; however, at least one study96 showed that VT was easier to induce in the presence of atrial fibrillation than of sinus rhythm, and the Framingham study reported higher mortality in patients with chronic atrial fibrillation than in controls.97 This raises the possibility that lack of significant risk may relate to inadequate evaluation of the issue.
Partial AV block (first-degree AV block or temporary second-degree AV block not associated with marked bradycardia), hypertension without LVH, and age >60 years as independent factors are not associated with sudden death and thus may be compatible with the diagnosis of IVF.
Similarly, isolated, modest thickening of the septum or free wall of the left ventricle (<10% greater than normal), regional dyskinesia, and isolated bundle-branch block do not identify a specific cause or association with sudden death and may therefore be considered compatible with the diagnosis of IVF.
RBBB associated with persistent ST-segment elevation has recently been defined as a form of IVF.24 However, evidence by Corrado et al98 suggests that this syndrome might represent one spectrum of right ventricular cardiomyopathy. These authors showed that within one family with right ventricular dysplasia, some members showed the ST-segment displacement, while others had the typical "epsilon" wave.99 Until more data support this view, there is not enough evidence to consider RBBB and ST-segment displacement alone as diagnostic for ARVD; therefore, patients with only these features should be considered to have a variant of IVF, but careful evaluation of the right ventricle should be performed at follow-up (Table 2).
|
Even though as of today it remains unclear whether patients with "absolutely no evidence of heart disease" differ from those with "some evidence of cardiac abnormality," it is important that any even minimal abnormality be recorded and followed over time to allow prospective evaluation of its prognostic value.
Finally, there are some clinical conditions that will be difficult or impossible to exclude despite careful investigations (Table 3). For example, the interpretation of electrolyte disturbance in patients resuscitated from cardiac arrest is often equivocal because many patients are hypokalemic because of catecholamine release after the event. Thus, it is difficult to ascribe hypokalemia as a cause of IVF unless there is a history of electrolyte imbalance, the patients are receiving medications known to deplete potassium or are on liquid protein diets, or there is documentation of severe electrolyte abnormalities when the patient is in steady state.
|
The relationship between clinical findings and causation of cardiac arrest must take into account that there is a continuous spectrum from completely normal to the frankly abnormal. Judgment on the role of equivocal abnormalities in triggering or conditioning the cardiac arrest must be based on the severity of the abnormality and the strength of the evidence for a link between the abnormality and the occurrence of cardiac arrest. Moreover, abnormalities are not isolated in time: they may be transient or evolutionary and in the latter case may remain undetectable for a long time after the index clinical event.100
|
Importance of Accurate Follow-up |
|---|
Several findings may be present that cannot be considered sufficient for a diagnosis but that, nonetheless, are suspicious and may be forerunners of a structural heart disease that will become apparent only with time. In these cases, although an initial diagnosis of IVF may be acceptable, a careful follow-up of the patient is necessary. Even in the absence of symptoms or of arrhythmia recurrence, all patients should probably receive a comprehensive clinical evaluation every year. Also, repeat echocardiograms and ECGs and Holter monitoring are recommended every year. The availability of follow-up data on a large number of IVF patients will be most valuable to allow the assessment of those individuals initially diagnosed as having IVF who will eventually develop structural heart disease; indeed, this is one of the major goals of the prospective registries.1
|
Conclusions |
|---|
The present document provides a basis for the definition of the clinical diagnosis of IVF and outlines the appropriate steps necessary to make this diagnosis. A unified and unequivocal definition and approach to diagnosis will avoid a danger always inherent in any diagnosis of exclusion, namely, that of a hasty diagnosis of IVF in a survivor of a cardiac arrest due instead to one of the many definite causes for VF. This will affect the therapeutic choice and probably deprive the unfortunate patient of a specific and more effective therapy. The eventual understanding of what we now call IVF will thus become largely possible together with information on the probability of recurrence, on the ways to identify subgroups at higher risk for such recurrence, and on the long-term effects of various therapies. The success of the prospective registries depends on the cooperation of physicians worldwide who encounter patients with IVF. Every physician willing to contribute to this project is invited to contact a member of the Steering Committee of the European or United States registries.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
UCARE is funded by BIOMED-1 grant CEE BMH1-CT92, by an educational grant of the European Society of Cardiology, and by a research grant of Medtronic Europe. The authors wish to thank Dr Vincenzo Paganini, UCARE Data Monitor, for his support and Pinuccia De Tomasi for editorial assistance.
|
Footnotes |
|---|
Reprint requests to Silvia G. Priori, MD, PhD, FESC, Dipartimento di Cardiologia, Policlinico S. Matteo, IRCCS, Piazzale Golgi 2, 27100 Pavia, Italy.
*UCARE is a research project of the Working Group on Arrhythmias of the European Society of Cardiology.
|
Appendix |
|---|
This article summarizes the outcome of a workshop held in New Orleans, La, on March 19, 1995. The need for the workshop was proposed by Silvia G. Priori and Peter J. Schwartz, who served as chairpersons. Participating in the workshop and coauthoring the paper were Gust H. Bardy (Seattle, Wash), J. Thomas Bigger Jr (New York, NY), Martin Borggrefe (Munster, Germany), A. John Camm (London, UK), Leonard A. Cobb (Seattle, Wash), Gordon A. Ewy (Tucson, Ariz), Richard N.W. Hauer (Utrecht, Netherlands), Karl-Heinz Kuck (Hamburg, Germany), Richard D. Lane (Tucson, Ariz), Ralph Lazzara (Oklahoma City,Okla), Frank I. Marcus (Tucson, Ariz), James E. Muller (Boston, Mass), Robert J. Myerburg (Miami, Fla), Silvia G. Priori (Pavia, Italy), Peter J. Schwartz (Pavia, Italy), Paul Touboul (Lyon, France), Richard L. Verrier (Boston, Mass), Hein J.J. Wellens (Maastricht, Netherlands), and Douglas P. Zipes (Indianapolis, Ind).
|
References |
|---|
1. Priori SG, Borggrefe M, Camm AJ, Hauer RNW, Klein H, Kuck KH, Schwartz PJ, Touboul P, Wellens HJJ. Unexplained cardiac arrest: the need of a prospective registry. Eur Heart J. 1992;13:1445-1446.
2. Priori SG, Borggrefe M, Camm AJ, Hauer RNW, Klein H, Kuck KH, Schwartz PJ, Touboul P, Wellens HJJ, on behalf of UCARE. Role of the implantable defibrillator in patients with idiopathic ventricular fibrillation: data from the UCARE international registry. Pacing Clin Electrophysiol. 1995;18(pt 2):799. Abstract.
3. Priori SG, Borggrefe M, Camm AJ, Hauer RNW, Klein H, Kuck KH, Schwartz PJ, Touboul P, Wellens HJJ. Role of programmed electrical stimulation in the identification of the effective pharmacologic therapy in patients with idiopathic ventricular fibrillation. Circulation. 1995;92(suppl I):I-97. Abstract.
4. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 4th ed. Philadelphia, Pa: WB Saunders Co; 1992:756-789.
5. Poole JE, Bardy GH. Sudden cardiac death. In: Zipes DP, Jalife J, Eds. Cardiac Electrophysiology: From Cell To Bedside. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1995:812-832.
6.
Friedman M, Manwaring JH, Rosenmann RH, Danlon G, Ortega P, Grube SM. Instantaneous and sudden death. JAMA. 1973;225:1319-1328.
7.
Raymand JR, van der Berg EK, Knapp MJ. Non traumatic pre-hospital sudden death in young adults. Arch Intern Med. 1988;148:303-308.
8. Myerburg RJ, Conde CA, Sung RJ, Mayorga-Cortes A, Mallon SM, Sheps DS, Appel RA, Castellanos A. Clinical, electrophysiologic and hemodynamic profile of patients resuscitated from pre-hospital cardiac arrest. Am J Med. 1980;68:568-576.[Medline] [Order article via Infotrieve]
9. Graboys TB, Lown B, Podrid PJ, De Silva R. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol. 1982;50:437-443.[Medline] [Order article via Infotrieve]
10.
Swerdlow CD, Bardy GH, McAnulty J, Kron J, Lee JT, Graham E, Peterson J, Greene HL. Determinants of induced sustained arrhythmias in survivors of out-of-hospital ventricular fibrillation. Circulation. 1987;76:1053-1060.
11. Trappe HJ, Brugada P, Talajic M, Della Bella P, Lezaun R, Mulleneers R, Wellens HJJ. Prognosis of patients with ventricular tachycardia and fibrillation: role of underlying etiology. J Am Coll Cardiol. 1988;12:166-174.[Abstract]
12. Poole JE, Mathisen TL, Kudenchuk PJ, McAnulty JH, Swerdlow CD, Bardy GH, Greene HL. Long-term outcome in patients who survive out of hospital ventricular fibrillation and undergo electrophysiologic studies: evaluation by electrophysiologic subgroups. J Am Coll Cardiol. 1990;16:657-665.[Abstract]
13. Sager PT, Choudhary R, Leon C, Rahimtoola SH, Bhandari AK. The long-term prognosis of patients with out-of hospital cardiac arrest but no inducible ventricular tachycardia. Am Heart J. 1990;120:1334-1342.[Medline] [Order article via Infotrieve]
14. Proclemer A, Vannuzzo D, Facchin D, Feruglio GA. Long term prognosis and risk stratification in patients with sustained ventricular tachyarrhythmias of different etiology. New Trends Arrhythmias. 1991;7:917-925.
15. Kudenchuk PJ, Cobb LA, Greene L, Fahrenbruch CE, Sheehan FH. Late outcome of survivors of out-of-hospital cardiac arrest with left ventricular ejection fraction >50% and without significant coronary arterial narrowing. Am J Cardiol. 1991;67:704-708.[Medline] [Order article via Infotrieve]
16. Martini B, Nava A, Thiene G, Buja GF, Canciani B, Scognamiglio R, Daliento L, Dalla Volta S. Ventricular fibrillation without apparent heart disease: description of six cases. Am Heart J. 1989;118:1203-1209.[Medline] [Order article via Infotrieve]
17. Meissner MD, Mosteller RD, Steinman RT, Akhtar M, Cannom D, Epstein A, Fogoros R, Liem LB, Marchlinski F, Myerburg R, Veltri E, Schuger C, Lehmann MH. Cardiac arrest in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy. J Am Coll Cardiol. 1991;17:92A. Abstract.
18. Wellens HJJ, Lemery R, Smeets JL, Brugada P, Gorgels AP, Cheriex EC, de Zwaan C. Sudden arrhythmic death without overt heart disease. Circulation. 1992;85(suppl I):I-92-I-97.
19. Lemery R, Brugada P, Della Bella P, Dugernier T, Wellens HJJ. Ventricular fibrillation in six adults without overt heart disease. J Am Coll Cardiol. 1989;13:911-916.[Abstract]
20. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol. 1993;4:356-368.[Medline] [Order article via Infotrieve]
21. Benson DW Jr, Benditt DG, Anderson RW, Dunnigan A, Pritzker MR, Kulik TJ, Zavoral JH. Cardiac arrest in young, ostensibly healthy patients: clinical, hemodynamic and electrophysiologic findings. Am J Cardiol. 1983;52:65-69.[Medline] [Order article via Infotrieve]
22. Aliot E, Sadoul N, de Chillou C. Les fibrillations ventriculaires primitives. Arch Mal Coeur. 1993;86:783-788.
23. Brooks R, Burgess JH. Idiopathic ventricular tachycardia: a review. Medicine. 1988;67:271-294.[Medline] [Order article via Infotrieve]
24. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol. 1992;20:1391-1396.[Abstract]
25. Bjerregaard P, Gussak I, Kotar SL, Gessler JE, Janosik D. Recurrent syncope in a patient with prominent J wave. Am Heart J. 1994;127:1426-1430.[Medline] [Order article via Infotrieve]
26. Proclemer A, Facchin D, Miani D, Feruglio GA. Tachicardia e fibrillazione ventricolare idiopatiche: inquadramento, diagnosi, terapia e prognosi. G Ital Cardiol. 1994;24:1027-1041.[Medline] [Order article via Infotrieve]
27.
Crijns HJGM, Wiesfeld ACP, Posma JL, Kong IL. Favourable outcome in idiopathic ventricular fibrillation with treatment aimed at prevention of high sympathetic tone and suppression of inducible arrhythmias. Br Heart J. 1995;74:408-412.
28. Siebels J, Schneider MAE, Geiger M, Kuck KH. Unexpected recurrences in survivors of cardiac arrest without organic heart disease. Eur Heart J. 1991;12(suppl):86. Abstract.
29.
Wever EFD, Hauer RNW, Oomen A, Peters RHJ, Bakker PFA, Robles de Medina EO. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation. 1993;88:1021-1029.
30.
Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med. 1993;119:1187-1197.
31. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol. 1993;4:356-368.
32.
Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantu F, Towbin AJ, Keating MT, Hammoude H, Brown AM, Chen LK, Colatsky TJ. Long QT syndrome patients with mutations on the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 1995;92:3381-3386.
33.
Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH, Keating MT, MacCluer JW, Timothy KW. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995;92:2929-2934.
34. Nava A, Rampazzo A, Buja G, Corrado A, Oselladore L, Thiene G, Danieli GA. The polymorphic clinical aspects of arrhythmogenic right ventricular cardiomyopathy are determined by genetic heterogeneity. New Trends Arrhythmias. 1995;11:677-680.
35.
Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moraavec CS, Seidman JG, Seidman CE. Mutations in the genes for cardiac troponin T and -tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332:1058-1064.
36. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805-811.[Medline] [Order article via Infotrieve]
37. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.[Medline] [Order article via Infotrieve]
38.
Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet. 1995;4:1603-1607.
39. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12:17-23.[Medline] [Order article via Infotrieve]
40. Stramba-Badiale M, Guffanti S, Porta N, Frediani M, Beria G, Colnaghi C. QT interval prolongation and cardiac arrest during antibiotic therapy with spiramycin in a newborn infant. Am Heart J. 1993;126:740-742.[Medline] [Order article via Infotrieve]
41.
Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic action of terfenadine. JAMA. 1993;269:1532-1536.
42. Priori SG, Diehl L, Schwartz PJ. Torsade de pointes. In: Podrid PJ, Kowey PR, eds. Cardiac Arrhythmia: Mechanisms, Diagnosis and Management. Baltimore, Md: William & Wilkins; 1995:951-963.
43.
Wannamethee G, Shaper AG. Alcohol and sudden cardiac death. Br Heart J. 1992;68:443-448.
44. Suhonen O, Aromaa A, Reunanen A, Knekt P. Alcohol consumption and sudden coronary death in middle aged Finnish men. Acta Med Scand. 1987;221:335-341.[Medline] [Order article via Infotrieve]
45. Gordon T, Kannel WB. Drinking habits and cardiovascular disease: the Framingham Study. Am Heart J. 1983;105:667-673.[Medline] [Order article via Infotrieve]
46. Goldman L. Cost effective strategy in cardiology. In: Braunwald E, ed. Heart Disease. Philadelphia, Pa: WB Saunders; 1992:1694-1707.
47. Ehsani A, Ewy GA, Sobel BE. Effects of electrical countershock on serum creatinine phosphokinase (CPK) activity. Am J Cardiol. 1976;37:12-18.[Medline] [Order article via Infotrieve]
48. Myerburg RJ, Kessler KM, Mallon SM, Cox MM, de Marchena E, Interian A Jr, Castellanos A. Life threatening ventricular arrhythmias in patient with silent myocardial ischemia due to coronary artery spasm. N Engl J Med. 1992;326:1451-1455.[Abstract]
49. Meeder JG, Mensink PBF, Tan ES, Criijns HJGM, Wiesfeld ACP, Blanksma PK, Pruim J, Vaalburg W, Lie KI. Evidence for myocardial perfusion heterogeneity and impaired perfusion reserve in idiopathic ventricular fibrillation. Eur Heart J. 1995;16(suppl):95. Abstract.
50. Noble J, Bourassa MG, Petitclerc R, Dyrda I. Myocardial bridging and milking effect of the left anterior descending coronary artery: normal variant or obstruction? Am J Cardiol. 1976;37:993-999.[Medline] [Order article via Infotrieve]
51. Kern KB, Rhee KH, Raya TE, Berg RA, Hilwig RW, Sanders AB, Otto CW, Ewy GA. Global myocardial stunning following successful resuscitation from cardiac arrest. Circulation. 1994;90(suppl I):I-5. Abstract.
52. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol. 1983;2:437-444.[Abstract]
53.
McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom P, Fontaine G, Camerini F. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J. 1994;71:215-218.
54. Fontaine G. Arrhythmogenic right ventricular dysplasia. Curr Opin Cardiol. 1995;10:16-20.[Medline] [Order article via Infotrieve]
55. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;4:361-370.
56.
Blake LM, Scheinman MM, Higgins CB. MR features of arrhythmogenic right ventricular dysplasia. Am J Roentgenol. 1994;162:809-812.
57.
Auffermann W, Wichter T, Breithardt G, Joachimsen K, Peters PE. Arrhythmogenic right ventricular disease: MR imaging vs angiography. Am J Roentgenol. 1993;161:549-555.
58.
Rampazzo A, Nava A, Danieli GA, Buja GF, Daliento L, Fasoli G, Scognamiglio R, Corrado D, Thiene G. The gene for arrhythmogenic right ventricular cardiomyopathy maps on chromosome 14q23-q24. Hum Mol Genet. 1994;3:959-962.
59. Rampazzo A, Nava A, Erne P, Eberhard M, Vian E, Slomp P, Tiso N, Thiene G. A new locus for arrhythmogenic cardiomyopathy (ARVD2) maps to chromosome 1q42-43. Hum Mol Genet. 1995;11:2151-2154.
60. Schwartz PJ, Locati EH, Napolitano C, Priori SG. The long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell To Bedside. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1995:788-811.
61.
Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval: a marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation. 1994;89:1681-1689.
62.
Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993;88:782-784.
63. Schwartz PJ, Malliani A. Electrical alternation of the T wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long QT syndrome. Am Heart J. 1975;89:45-50.[Medline] [Order article via Infotrieve]
64. Malfatto G, Beria G, Sala S, Bonazzi O, Schwartz PJ. Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. J Am Coll Cardiol. 1994;23:296-301.[Abstract]
65. Lehmann MH, Suzuki F, Fromm BS, Francovich D, Elko P, Steinman RT, Fresard J, Baga JJ, Taggart RT. T wave "humps" as a potential electrocardiographic marker of the long QT syndrome. J Am Coll Cardiol. 1994;24:746-754.[Abstract]
66. Priori SG. Is long QT syndrome entering the era of molecular diagnosis? Heart. In press.
67. Ohe T, Aihara N, Kamakura S, Kurita T, Shimizu W, Shimonura K. Long-term outcome of verapamil-sensitive sustained left ventricular tachycardia in patients without structural heart disease. J Am Coll Cardiol. 1995;25:54-58.[Abstract]
68.
Gaita F, Giustetto C, Leclercq JF, Haissaguerre M, Riccardi R, Libero L, Baralis G, Brusca A, Coumel P, Warin JF. Idiopathic verapamil-responsive left ventricular tachycardia: clinical characteristics and long-term follow up of 33 patients. Eur Heart J. 1994;15:1252-1260.
69.
Buxton AE, Waxman HL, Marchlinski FE, Simson MB, Cassidy D, Josephson ME. Right ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation. 1983;68:917-927.
70.
Lemery R, Brugada P, Della Bella P, Dugernier T, van den Dool A, Wellens HJJ. Nonischemic ventricular tachycardia: clinical course and long-term follow-up in patients without clinically overt heart disease. Circulation. 1989;79:990-999.
71. Coumel P, Fidelle J, Lucet V, Attuel P, Bouvrain Y. Catecholamine-induced severe ventricular arrhythmias with Adam-Stokes syndrome in children: report of four cases. Br Heart J. 1978;40(suppl):28-37.
72. Eisenberg SJ, Scheinman MM, Dullet NK, Finkbeiner WE, Griffin JC, Eldar M, Franz MR, Gonzalez R, Kadish AH, Lesh MD. Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QTc intervals and normal systolic cardiac function. Am J Cardiol. 1995;75:687-692.[Medline] [Order article via Infotrieve]
73.
Leenhardt A, Glaser E, Burguera M, Nurnberg M, Maison-Blanche P, Coumel P. Short-coupled variant of torsade de pointes: a new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994;89:206-215.
74.
Belhassen B, Shapira I, Shoshani D, Parades A, Miller H, Laniado S. Idiopathic ventricular fibrillation: inducibility and beneficial effect of class I antiarrhythmic agents. Circulation. 1987;75:809-816.
75. Munger RG, Weniger BG, Warintrawat S, Kunasol P, van der Werff H, van Bruggen G, Paquet C, Holtan NR. Sudden death in sleep of South-East Asian refugees. Lancet. 1986;2:1093-1094.[Medline] [Order article via Infotrieve]
76.
Kirschner RH, Eckner FAO, Baron RC. The cardiac pathology of sudden, unexplained nocturnal death in Southeast Asian refugees. JAMA. 1986;256:2700-2705.
77. Nimmannit S, Malasit P, Chaovakul V, Susaengrat W, Nilwarangkur S. Potassium and sudden unexplained nocturnal death. Lancet. 1990;336:116-117.
78. Munger RG, Booton EA. Thiamine and sudden death in sleep of South-East Asian refugees. Lancet. 1990;335:1154-1155.
79.
Robinson K, Rowland E, Krikler DM. Latent pre-excitation: exposure of anterograde accessory pathway conduction during atrial fibrillation. Br Heart J. 1988;59:53-55.
80. Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. 1979;301:1080-1085.[Abstract]
81. Wellens HJJ, Brugada P, Roy D, Weiss J, Bar FW. Effect of isoproterenol on anterograde refractory period of the accessory pathway in patients with Wolff-Parkinson-White syndrome. Am J Cardiol. 1982;50:180-184.[Medline] [Order article via Infotrieve]
82.
Phillips MP, Robinowitz M, Higgins JR, Boran KJ, Reed T, Virmani R. Sudden cardiac death in Air Force recruits. JAMA. 1986;256:2696-2699.
83.
Mason JW, O'Connell JB. Clinical merit of endomyocardial biopsy. Circulation. 1989;79:971-979.
84.
Strain JE, Grose RM, Factor SM, Fisher JD. Results of endomyocardial biopsy in patients with spontaneous ventricular tachycardia but without apparent structural heart disease. Circulation. 1983;68:1171-1181.
85. Sugrue DD, Holmes DR, Gersh BJ, Edwards WD, McLaran CJ, Wood DL, Osborn MJ, Hammill SC. Cardiac histologic findings in patients with life-threatening ventricular arrhythmias of unknown origin. J Am Coll Cardiol. 1984;4:952-957.[Abstract]
86.
Morgera T, Salvi A, Alberti E, Silvestri F, Camerini F. Morphological finding in apparently idiopathic ventricular tachycardia: an echocardiographic haemodynamic and histologic study. Eur Heart J. 1985;6:323-334.
87.
Hosenpud JD, McAnulty JH, Niles NR. Unexpected myocardial disease in patients with life-threatening arrhythmias. Br Heart J. 1986;56:55-61.
88. Shmorhun D, Fenrich A, Cecchin F, Martini A, Friedman R, Kearney D, Ni J, Kim YH, Towbin JA. Ventricular tachycardia in a young population: the role of PCR analysis. Pediatrics. 1996;98:528. Abstract.
89. Kinney EL, Jackson GL, Reeves WC, Zelis R. Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction: an analysis of 44 patients. Am J Med. 1980;68:1980-1985.
90. Kligfield P, Levy D, Devereux RB, Savage DD. Arrhythmias and sudden death in mitral valve prolapse. Am Heart J. 1987;113:1298-1307.[Medline] [Order article via Infotrieve]
91.
Campbell RWF, Godman MG, Fiddler GI, Marquis RM, Julian DG. Ventricular arrhythmias in syndrome of balloon deformity of mitral valve: definition of possible high risk group. Br Heart J. 1976;38:1053-1057.
92.
Bekheit SG, Ali AA, Deglin SM, Jain AC. Analysis of QT interval in patients with idiopathic mitral valve prolapse. Chest. 1982;81:620-624.
93. Pocock WA, Bosman CK, Chesler E, Barlow JB, Edwards JE. Sudden death in primary mitral valve prolapse. Am Heart J. 1984;107:378-382.[Medline] [Order article via Infotrieve]
94. Nishimura RA, McGoon MD, Shub C, Miller FA Jr, Ilstrup DM, Tajik AJ. Echocardiographically documented mitral valve prolapse: long term follow up of 237 patients. N Engl J Med. 1985;313:1305-1309.[Abstract]
95. Marks AR, Choon CY, Chir MBB, Sanfilippo AJ, Ferre M, Weyman AE. Identification of high-risk and low-risk subgroups of patients with mitral-valve prolapse. N Engl J Med. 1989;320:1031-1036.[Abstract]
96. Rostagno C, Bacci F, Martelli M, Naldoni A, Bertini G, Gensini GF. Clinical course of atrial fibrillation since first symptomatic arrhythmic episode. Am J Cardiol. 1995;76:837-839.[Medline] [Order article via Infotrieve]
97. Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1987;306:1018-1022.[Abstract]
98. Corrado P, Nava A, Buja G, Martini B, Fasoli G, Oselladore L, Turrini P, Thiene G. Familial cardiomyopathy underlies syndrome of right bundle branch block, ST segment elevation and sudden death. J Am Coll Cardiol. 1996;27:443-448.[Abstract]
99.
Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgogeat Y. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384-398.
100.
Deal BJ, Miller SM, Scagliotti D, Prechel D, Gallastegui JL, Hariman RJ. Ventricular tachycardia in a young population without overt heart disease. Circulation. 1986;73:1111-1118.
This article has been cited by other articles:
 |
|
 |
|
  E. M. Aliot, W. G. Stevenson, J. M. Almendral-Garrote, F. Bogun, C. H. Calkins, E. Delacretaz, P. D. Bella, G. Hindricks, P. Jais, M. E. Josephson, et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA) Europace, June 1, 2009; 11(6): 771 - 817. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Akutsu, K. Kaneko, Y. Kodama, H.-L. Li, M. Kawamura, T. Asano, K. Tanno, A. Shinozuka, T. Gokan, and Y. Kobayashi The Significance of Cardiac Sympathetic Nervous System Abnormality in the Long-Term Prognosis of Patients with a History of Ventricular Tachyarrhythmia J. Nucl. Med., January 1, 2009; 50(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Eckardt, G&#x.;n. Breithardt, and S. Hohnloser CHAPTER 30 Ventricular Tachycardia and Sudden Cardiac Death ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pieroni, F. Bellocci, F. Crea, I. Nault, M. Wright, and M. Haissaguerre Sudden Cardiac Arrest Associated with Early Repolarization N. Engl. J. Med., August 14, 2008; 359(7): 761 - 762. [Full Text] [PDF]
|
|
|
|
|
|
M. Haissaguerre, N. Derval, F. Sacher, L. Jesel, I. Deisenhofer, L. de Roy, J.-L. Pasquie, A. Nogami, D. Babuty, S. Yli-Mayry, et al. Sudden Cardiac Arrest Associated with Early Repolarization N. Engl. J. Med., May 8, 2008; 358(19): 2016 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Noda, W. Shimizu, A. Taguchi, T. Aiba, K. Satomi, K. Suyama, T. Kurita, N. Aihara, and S. Kamakura Malignant Entity of Idiopathic Ventricular Fibrillation and Polymorphic Ventricular Tachycardia Initiated by Premature Extrasystoles Originating From the Right Ventricular Outflow Tract J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1288 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Lane, C. Laukes, F. I. Marcus, M. A. Chesney, L. Sechrest, K. Gear, C. L. Fort, S. G. Priori, P. J. Schwartz, and A. Steptoe Psychological Stress Preceding Idiopathic Ventricular Fibrillation Psychosom Med, May 1, 2005; 67(3): 359 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Chugh, O. Senashova, A. Watts, P. T. Tran, Z. Zhou, Q. Gong, J. L. Titus, and S. J. Hayflick Postmortem molecular screening in unexplained sudden death J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1625 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. D. Wever and E. O. Robles de Medina Sudden death in patients without structural heart disease J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Priori, C. Napolitano, M. Memmi, B. Colombi, F. Drago, M. Gasparini, L. DeSimone, F. Coltorti, R. Bloise, R. Keegan, et al. Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Circulation, July 2, 2002; 106(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Callans Management of the Patient Who Has Been Resuscitated From Sudden Cardiac Death Circulation, June 11, 2002; 105(23): 2704 - 2707. [Full Text] [PDF]
|
|
|
|
 |
|
 R.N.W. Hauer, E. Aliot, M. Block, A. Capucci, B. Luderitz, M. Santini, and P.E. Vardas Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology Eur. Heart J., July 1, 2001; 22(13): 1074 - 1081. [PDF]
|
|
|
|
 |
|
 P Mazeika Aborted sudden cardiac death: a clinical perspective Postgrad. Med. J., June 1, 2001; 77(908): 363 - 370. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. G Priori, C. Napolitano, and M. Grillo Concealed arrhythmogenic syndromes: the hidden substrate of idiopathic ventricular fibrillation? Cardiovasc Res, May 1, 2001; 50(2): 218 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Corrado, C. Basso, and G. Thiene Sudden cardiac death in young people with apparently normal heart Cardiovasc Res, May 1, 2001; 50(2): 399 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.A Remme, E.F.D Wever, A.A.M Wilde, R Derksen, and R.N.W Hauer Diagnosis and long-term follow-up of the Brugada syndrome in patients with idiopathic ventricular fibrillation Eur. Heart J., March 1, 2001; 22(5): 400 - 409. [Abstract] [PDF]
|
|
|
|
|
|
R. N. W. Hauer, E. Aliot, M. Block, A. Capucci, B. Luderitz, M. Santini, and P. E. Vardas Indications for implantable cardioverter defibrillator (ICD) therapy: Study Group on Guidelines on ICD of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology Europace, January 1, 2001; 3(3): 169 - 176. [PDF]
|
|
|
|
|
|
S. S. Chugh, K. L. Kelly, and J. L. Titus Sudden Cardiac Death With Apparently Normal Heart Circulation, August 8, 2000; 102(6): 649 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jahangiri, E. A. Shinebourne, D. Zurakowski, M. L. Rigby, A. N. Redington, and C. Lincoln Subclavian flap angioplasty: Does the arch look after itself? J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 224 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Viskin, R Fish, M Eldar, D Zeltser, M D Lesh, A Glick, and B Belhassen Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls Heart, July 1, 2000; 84(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Stevenson and H. T. Aretz Case 20-2000- A 61-Year-Old Man with a Wide-Complex Tachycardia N. Engl. J. Med., June 29, 2000; 342(26): 1979 - 1987. [Full Text] [PDF]
|
|
|
|
|
|
D. P. Chevalier, D. P. Touboul, D. P. Zipes, and H. J. J. Wellens Calcium-Channel Blockers and Cardiac Arrest • Response Circulation, December 21, 1999; 100 (25): e140 - e140. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Crawford, S. J. Bernstein, P. C. Deedwania, J. P. DiMarco, K. J. Ferrick, A. Garson Jr, L. A. Green, H. L. Greene, M. J. Silka, P. H. Stone, et al. ACC/AHA guidelines for ambulatory electrocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography) developed in collaboration with the North American Society for Pacing and Electrophysiology J. Am. Coll. Cardiol., September 1, 1999; 34(3): 912 - 948. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Scanlon, D. P. Faxon, A.-M. Audet, B. Carabello, G. J. Dehmer, K. A. Eagle, R. D. Legako, D. F. Leon, J. A. Murray, S. E. Nissen, et al. ACC/AHA guidelines for coronary angiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1756 - 1824. [Full Text] [PDF]
|
|
|
|
|
|
S. G. Priori, J. Barhanin, R. N. W. Hauer, W. Haverkamp, H. J. Jongsma, A. G. Kleber, W. J. McKenna, D. M. Roden, Y. Rudy, K. Schwartz, et al. Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Parts I and II Circulation, February 2, 1999; 99(4): 518 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.G. Priori, J. Barhanin, R.N.W. Hauer, W. Haverkamp, H.J. Jongsma, A.G. Kleber, W.J. McKenna, D.M. Roden, Y. Rudy, K. Schwartz, et al. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management Eur. Heart J., February 1, 1999; 20(3): 174 - 195. [PDF]
|
|
|
|
|
|
D. P. Zipes and H. J. J. Wellens Sudden Cardiac Death Circulation, November 24, 1998; 98(21): 2334 - 2351. [Full Text] [PDF]
|
|
|
|
|
|
E. H. Locati, W. Zareba, A. J. Moss, P. J. Schwartz, G. M. Vincent, M. H. Lehmann, J. A. Towbin, S. G. Priori, C. Napolitano, J. L. Robinson, et al. Age- and Sex-Related Differences in Clinical Manifestations in Patients With Congenital Long-QT Syndrome : Findings From the International LQTS Registry Circulation, June 9, 1998; 97(22): 2237 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wichter, P. Matheja, L. Eckardt, P. Kies, K. Schafers, E. Schulze-Bahr, W. Haverkamp, M. Borggrefe, O. Schober, G. Breithardt, et al. Cardiac Autonomic Dysfunction in Brugada Syndrome Circulation, February 12, 2002; 105(6): 702 - 706. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||